Related Experiment Videos
Where are we with postmenopausal hormone therapy in 2005?
Po M Lam1, Tony K H Chung, Christopher Haines
1Department of Obstetrics and Gynecology, Prince of Wales Hospital, Hong Kong SAR, China. lamponmui@cuhk.edu.hk
Summary
Postmenopausal hormone therapy has raised controversies, particularly regarding cardiovascular health. This review examines key trials like the Heart and Estrogen/progestin Replacement Study (HERS) and Women's Health Initiative (WHI), discussing current knowledge and emerging alternatives.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Women's Health
Background:
- Long-term postmenopausal hormone therapy has been a subject of debate.
- Two major randomized controlled trials, HERS and WHI, have generated significant discussion regarding cardiovascular outcomes.
- Understanding the risks and benefits of hormone therapy is crucial for postmenopausal women.
Purpose of the Study:
- To review the findings of the Heart and Estrogen/progestin Replacement Study (HERS) and the Women's Health Initiative (WHI).
- To discuss the current understanding of postmenopausal hormone therapy's effects, especially on cardiovascular health.
- To explore emerging therapeutic options like raloxifene and tibolone.
Main Methods:
- Review of two large, randomized, placebo-controlled trials: HERS and WHI.
- Analysis of published data focusing on cardiovascular aspects.
- Discussion of evidence for alternative treatments.
Main Results:
- HERS and WHI studies introduced significant controversies regarding hormone therapy's cardiovascular impact.
- The results highlight complexities and uncertainties in the long-term use of hormone replacement therapy.
- Evidence on novel agents like raloxifene and tibolone is also considered.
Conclusions:
- Postmenopausal hormone therapy's cardiovascular effects remain a complex and debated topic.
- Further research is needed to clarify the risks and benefits.
- Novel therapeutic options may offer alternatives with different risk-benefit profiles.